
|Videos|April 14, 2016
Dr. Jeffrey Jones on Idelalisib and Ibrutinib in Patients With CLL
Author(s)Jeffrey Jones, MD
Jeffrey Jones, MD, discusses treatment options for patients with chronic lymphocytic leukemia (CLL) who progress on, or become intolerant of, idelalisib or ibrutinib during their treatment.
Advertisement
Jeffrey Jones, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL) who progress on, or become intolerant of, idelalisib or ibrutinib during their treatment. Jones says one option is to begin salvage treatment with either idelalisib or ibrutinib after one of the two treatment options fails. Utilizing the treatment option not initially chosen has resulted in about a 50% response rate.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
4
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
5




















